Summary The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks and side-effects of either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects of their combination on cardiovascular risk factors within a prevention trial of tamoxifen. Baseline and 1 2-month measurements of total, low-density lipoprotein (LDL)-and high-density lipoprotein (HDL)-cholesterol, platelets and white blood cells were obtained in the following four groups: tamoxifen (n = 1117), placebo (n = 1112), tamoxifen and HRT (n = 68), placebo and HRT (n = 87). The analysis was further extended to women who were on HRT at randomization but discontinued it during the 12-month intervention period (n= 33 on tamoxifen and n = 35 on placebo) and to women who were not on HRT but started it during intervention (n = 36 in both arms of the study). Compared with small changes in the placebo group, tamoxifen was associated with changes in total, LDL-and HDL-cholesterol of approximately -90/, -19% and +0.2% in continuous HRT users compared with -9%/6, -14% and -0.8% in never HRT users. Similarly, there was no interaction on platelet count. In contrast, the decrease in total and LDL-cholesterol levels induced by tamoxifen was blunted by two-thirds in women who started HRT while on tamoxifen (P = 0.051 for the interaction term). We conclude that the beneficial effects of tamoxifen on cardiovascular risk factors are unchanged in current HRT users, whereas they may be attenuated in women who start transdermal HRT while on tamoxifen. Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity.
The oestrogen receptor modulator tamoxifen is the standard endocrine treatment for breast cancer both in the palliative and in the adjuvant setting (Jaiyesimi et al. 1995) . In light of the substantial reduction in contralateral breast cancer observed in the worldwide meta-analysis of adjuvant studies (Early Breast Cancer Trialists Collaborative Group. 1998 ). this compound is currently being tested as a breast cancer preventive agent in controlled trials. An interim analysis of the US prevention trial involving 13 388 participants has led to the early closure of the study (Smigel. 1998) . It was shown that tamoxifen can approximately halve the incidence of breast cancer and decrease by 35% the incidence of osteoporotic bone fractures. Compared with the placebo group. however. women aced 50 or older receiving tamoxifen had more than a twofold increased risk of early-stage endometrial cancer and a threefold increased risk of pulmonary embolism. Altogether.
these results underline the importance of strategies aimed at reducing tamoxifen's toxicity while retaining its activity. particularly in post-menopausal women.
Given its pleiotropic pharmacological profile. which partly reflects the complexity of the oestrogen signalling in the body (Katzenellebogen. 1996 : Yang et al. 1996 . tamoxifen has either (Love et al. 1990 : Nayfield. 1995 . an effect that has been associated with a reduction in coronary heart disease in several adjuvant trials (Rutqvist et al. 1993 : McDonald et al. 1995 : Costantino et al. 1997 . Like oestrogen replacement therapy. tamoxifen may sporadically promote endometrial carcinorenesis (Fisher et al. 1994 . Rutqvist et al. 1995 and deep venous thrombosis (Fisher et al. 1989 : McDonald et al. 1995 . Finally. tamoxifen has shown opposite effects on bone mineral density depending upon menopausal status . and its administration tends to exacerbate menopausal effects such as vasomotor and urogenital symptoms. particularly in premenopausal women (Fisher et al. 1989 : Love et al. 1991 : Powles et al. 1994 . One important issue is the potential benefit of the combination of tamoxifen with hormone replacement therapy (HRT). the use of which has received increased attention since the introduction of the more physiological and better tolerated transdermal route of administration (Belchetz. 1994 : Nachtigall. 1995 . Indeed.HRT could minimize several disturbing effects of tamoxifen. such as hot flushes. vaginal dryness or discharge and urinary disturbances.
which may affect long-term compliance (Fisher et al. 1989 : Love et al. 1991 : Powles et al. 1994 . From another perspective. tamoxifen could reduce the risk of breast cancer in HRT users (Collaborative Group on Hormonal Factors in Breast Cancer. 1997: Grodstein et al. 1997) . even though the long-term effects of HRT administered *See Acknowledgements by transdermal route are unknown. In addition to the preventive context, the combined use of tamoxifen and HRT could increase both quantity and quality of life in breast cancer survivors. particularly those who had a premature menopause following chemotherapy and/or hormonal deprivation (Roy et al, 1996) .
It is currently unknown, however, whether the combined use of tamoxifen and HRT modifies the individual effect of either. Indeed. a multiplicative effect between the two agents, be it antagonistic or synergistic, would have important implications in terms of biological effects and clinical efficacy. For instance, an antagonistic interaction could reduce the efficacy of tamoxifen against breast cancer or blunt the cardiovascular benefit of both agents.
To provide insight into this issue, we studied within a primary prevention trial the effect of the combination of tamoxifen and HRT on serum cholesterol, an oestrogen-regulated target and an established surrogate end point biomarker of coronary heart disease (Holme, 1990) . The effects of tamoxifen and HRT were also studied on platelet (Plt) and white blood cell (WBC) counts. inasmuch as both parameters are affected by tamoxifen treatment (Powles et al, 1994; Lukac et al, 1995) and their levels have been positively associated with an increased risk of coronary heart disease in prospective studies (Thaulow et al. 1991; Gillum et al. 1993 ). A total of 3479 women were in the breast cancer trial with a potential follow-up time of at least 12 months. Women who were recently randomized or who withdrew from the study within 12 months of randomization were not considered. Because of some leeway in the scheduling of these follow-up visits, women whose 6-month visit did not take place within 4 and 7 months from randomization and whose 12-month visit took place at more than 15 months from randomization were excluded. No 12-month visit took place earlier than 10 months from randomization. This was done to ensure that all women were on the study from approximately the same length of time. The number of women who did not meet these criteria was 241. Almost all because the 12-month visit did not take place.
MATERIALS AND METHODS
Based on the information collected at baseline, and at 6 and 12 months, HRT was used at some time during the study by 705 of 3479 women with a possible 12-month follow-up. However, not all women in the analysis data set were on HRT throughout the 12-month period. The information available was HRT use at 0 (baseline). 6 and 12 months, duration of use, type of HRT. route of administration and dose.
At baseline 538 women were on HRT. Of these. 338 had already been on transdermal HRT for some time (among which seven were on combined oestroprogestin treatment and 331 on oestrogen alone). Of the 200 remaining cases on HRT at baseline. women were on transdermal oestrogen plus oral progestagen (n = 61). oral conjugated oestrogen (n = 47), oral progestagen (n = 17). intramuscular oestroprogestagen (n = 33), oral contraceptives (n = 8) and other types of HFI. including unspecified forms (n = 34). For the transdermal HRT group, dose information was reported in 89% of the cases; of these. 75% were treated with a daily dose of 50 pg. 22% with 25 jg and 3% with 100 jig of oestradiol.
The two easiest groups to consider were those women who were never on HRT (2774 women) and. secondly. those women who were on HRT throughout the study period (the 'always' group) (n = 308). The rest used HRT for part of the intervention period and two other groups were readily identifiable: those women who were on HRT at baseline but were not on HRT at 12 months (n = 181), and those women who were not on HRT at baseline but were on HRT at 12 months (n = 135). The remaining 81 women did not have complete HRT information at all three time points or had irregular HRT use. Irregular HRT use occurred when a woman was on HRT at 0 and 12 months but not at 6, or off HRT at 0 and 12 but on at 6 months, or did not use HRT regularly for long periods. Women with incomplete or irregular HRT histories were excluded.
In summary, the inclusion criteria were oestrogen-based HRT. the transdermal route of administering HRT and 6-and 12-month visits within the appropriate time windows. Women with irregular HRT use were also excluded. In total, 554 women of the 3479 with a 12-month follow-up were excluded from the analysis, leaving 2925 women. Of those women excluded from the analysis, 241 did not satisfy the time window criteria, 81 had incomplete HRT information or irregular HRT use, 200 did not have Utansdernal or oestrogen HRT at baseline, 145 at 6 months and 152 at 12 months. These numbers add up to more than 554 as many women were excluded for multiple reasons. Comparison was made initially of 155 women who were on transdermal HRT throughout the study period (68 on tamoxifen and 87 on the placebo) and 2229 women who were not on any form of HRT during the study period (1117 on tamoxifen and 1112 on the placebo). Investigation was then also made of 68 women who were on tansdernal HRT at baseline but not at 12 months (33 on tamoxifen and 35 on placebo) and 72 women who were not on transdermal HRT at 12 months but had not been at baseline (36 in both arms of the study). The four HRT groups are referred to as 'always', 'never', 'yes then off' and 'no then on'.
Total cholesterol (T-C) and high-density lipoprotein cholesterol (HDL-C) levels were measured by standard enzymatic methods using automatic analysers in laboratories participating in national standardization programmes. Low-density lipoprotein cholesterol (LDL-C) was determined according to the method of Friedewald et al (1972) . Although this formula implies the measurement of triglycerides, their values were not recorded in the study data forms. The T-C/HDL-C ratio was also calculated to better express the index of cardiovascular risk (Kinosian et al. 1994) .
The main end point of the study was the change in T-C levels from baseline to 12 months. The effect of tamoxifen and HRT use on this change was estimated by a linear regression model. The interaction between tamoxifen use and HRT use was the main variable to test Adjustment was made for age, body mass index (BMI; kg m-2), smoking and initial cholesterol level. The normality assumption of the change in cholesterol was assessed by normal plots. in BMI less than 25).
The changes in blood measurements over the 12-month interxention period are presented in Table 2 . For all cholesterol measures. there was no influence of HRT on the effect of tamoxifen in the chance in the levels over 12 months. At the average baseline T-C of 231 mg dl -there was a 20.3 + 1.3 ma dl-' mean reduction in T-C corresponding to a 9 ± 0.6%e reduction from baseline with tamoxifen (P < 0.01). but the reduction was the same irrespective of the HRT status (never or always. P = 0.36 for the interaction term). In both placebo and tamoxifen groups. the chance in T-C level was related to baseline T-C level. with a greater reduction the higher the baseline. Further. the reduction was greater in the tamoxifen group (P = 0.001) (Figure 1 ). In the placebo group there was no effect of age on T-C levels. whereas the effect of tamoxifen was greater among older women. adjusting for the effects of baseline T-C (P = 0.003) (Figure 2 ). Adjusting for baseline T-C and age and their interactions with tamoxifen there was no effect of BMI on the reduction in T-C (P = 0.50). These interpretations for T-C apply also to LDL-C and T-C/HDL-C ratio.
With HDL-C there was no evidence of any effect of age. although there was a negative BMI effect applicable to both tamoxifen and placebo groups (P = 0.001). Moreover. the modest. albeit significant. inhibitory effect of tamoxifen on HDL-C A as greater among women with a high HDL-C at baseline (P = 0.01 2).
With Plt count. there was a significant reduction in the tamoxifen group (Table 2) . Moreover. there was a slightly greater reduction in the placebo group with higher BMI in contrast to an increase in the tamoxifen group (P < 0.01 for the interaction term).
There was a trend to a synergistic interaction between tamoxifen and HRT use with regard to WBC count: although there was no chance in WBC count with placebo in the two HRT groups. there was a greater. albeit modest. reduction if a woman A-as on tamoxifen and continuous HRT (P = 0.04. Table 2 ).
The analysis was further extended to the four groups of intermittent HRT users. whose baseline characteristics. including HRT dose and blood measurements. were evenly distributed among groups. Although the HRT doses were similar to those employed by continuous HRT users (i.e. 70% received 50 og and 30'% 25~rg dax-' oestradiol). similar results were observed only for HDL-C.
WBC and PIt counts but not for T-C and LDL-C levels (Table 3 ).
Indeed. with T-C there xxas evidence of a borderline antagonist interaction between tanoxifen and HRT use (P = 0.051). This manifests itself in the group that was not on HRT at the beginning of the study but that subsequently went on continuous HRT. In this group there xxas no evidence of the average 20 mg dl-1 reduction in T-C observed in the other groups (Table 3) . A similar feature was noticed with LDL-C. although its significance xxas reduced xx hen the variables that influence LDL-C (i.e. age and baseline LDL-C) were included.
DISCUSSION
On theoretical grounds. the combination of tamoxifen and HRT could reduce risks and side-effects of either treatment. thus contributing to post-menopausal women's health in a substantial way. In fact. although HRT prevents post-menopausal symptoms and may reduce overall morbidity and mortality by affecting several important diseases such as coronarx heart disease (Grodstein et al. 1997) . osteoporotic fractures (Riggs et al. 1992) and colon cancer (Newcomb et al. 1995 : Grodstein et al. 1997 ). the addition of tamoxifen could prexent the increased risk in breast cancer incidence and mortalits associated x ith HRT use (Collaborative Group on Hormonal Factors in Breast Cancer.
1997 : Grodstein et al. 1997) . Furthermore. HRT use could minimize most tamoxifen side-effects (Fisher et al. 1989 . including a progressive rise in endogenous oestrogens in premenopausal women (Jordan et al. 1991) . some of which max seriously affect treatment compliance. particularly in a preventix e setting (Powles et al. 1994 ). Moreover. concomitant HRT including progestins might even affect the risk of endometrial cancers during tamoxifen. as the xero large majority of these cases were observed in post-menopausal xxomen (Assikis et al. 1996) .
Given the complex pharmacological profile of tamoxifen. which partly depends on the woman's endocrine milieu (Gallo et al. 1997) . it is. however. important to evaluate the occurrence of potential interactions between tamoxifen and HRT before considerinc anv clinical trial of their combination. Moreover. as HRT use is allowed in the tamoxifen prevention trials. this study permits a useful initial assessment of such interactions. The main conclusion of our study' using this data is that tamoxifen has a similar effect on in HDL-C induced by tamoxifen was not modified by HRT use. Similar results were observed on Plt count. whereas a modest synergistic interaction was observed on WBC count. However, the clinical significance of this interaction is unclear. Overall, these results indicate that tamoxifen can be added to transdermal HRT without modifying their relevant biological effects. thus supporting the conclusions of previous pilot studies in women with breast cancer (Powles et al. 1993) and in healthy at-risk women (Chang et al. 1996) .
However. in contrast with the findings of the main analysis. a border-line antagonistic interaction on T-C and T-C/HDL-C and, to a lesser extent, on LDL-C levels was observed in the group that started HRT during tamoxifen intervention. Specifically. the 9% reduction in T-C and T-C/HDL-C levels in the tamoxifen group was blunted by two-thirds after the initiation of HRT. Although this conclusion should be treated with caution, given the limited number of cases and the borderline significance level, the observation that the number of women starting HRT during intervention was similar in the tamoxifen and placebo arms of the study seems to exclude the bias of an uneven HRT prescription. Moreover. the finding was not due to a dose dependence of the interaction, as oestadiol doses were similar in continuous and intermittent HRT users, nor to a higher rate of withdrawal from tamoxifen in the women who started HRT during the trial (not shown). Also. although this analysis may not be robust in view of the small numbers in this arm of our observational study, we have doubled the number of subjects in comparison with the previous study by Chang et al (1996) . where the same pattem of response is also evident among women prescribed HRT while recently given tamoxifen.
Another important finding of our study is the observation that the inhibitory effect of tamoxifen on cholesterol measures was modified by age and baseline cholesterol levels, a greater reduction being observed in older women and in women with higher baseline concentrations. This would imply that the magnitude of the preventive efficacy of tamoxifen on coronary heart disease will be more pronounced in these higher risk categories, thus achieving a substantial reduction in terms of cardiovascular events (Holme. 1990; Smith et al. 1993) . Moreover, the significant decrease in Plt count, another factor associated with cardiovascular morbidity (Thaulow et al, 1991; Handin. 1996) . might further contribute to the protective effect of tamoxifen. In this regard. the expected reduction in cardiovascular events by tamoxifen based on its effects on the lipid profile is approximately 20% (Costantino et al. 1997) . an estimation that will be verified in the ongoing prevention trials.
Admittedly. there are some limitations to our study. Firstly.
women on HRT represent a subgroup in the trial and were not randomized to HRT use. Consequently. we cannot exclude the possibility that the population receiving HRT was selected based on a higher cholesterol level than non-users, although the mild modulation of cholesterol measures observed in de novo HRT users in the placebo group seems to discount this possibility. Secondly, lipid measurements and blood cell counts were not centralized, although these measures are obtained by routine standard techniques and there is no reason to believe that inter-laboratory-variation was unevenly distributed among the groups. Finally, the spectrum of the end points analysed in our study was relatively limited, as other important oestrogenic markers such as the haemostasis profile, bone mass and mammographic density were not measuredAgainst these limitations, it is important to consider that our results were obtained in a selected population, namely hysterectomized women, where the incidence of cardiovascular risk factors is likely to be higher than in the general population (Rosemberg et al. 1981) . Indeed. 47% of the women in the study were aged over 50 years and 37% of those under the age of 50 had a premature menopause as a result of a bilateral oophorectomy. In addition. the lack of progestin in virtually all HRT users should be considered in the evaluation of cholesterol results, although oral progestins such as medroxyprogesterone acetate do not seem to attenuate the effects of oestrogen replacement therapy both on cardiovascular risk factors (The writing group for the PEPI trial. 1995) and events (Grodstein et al. 1996 (Grodstein et al. . 1997 . Finally, our conclusions are restricted to the use of transdermal HRT and may not be applicable to oral HRT. In fact our data confirm the limited effect exerted by transdermal HRT on the lipid profile that has already been observed in most previous studies (Chetkowsky et al. 1986 : Colvin et al, 1990 : Walsh et al. 1994 . In contrast, the four to fivefold increased oestrogen concentration reached in the hepatic circulation by oral HRT leads to profound lipid and protein changes (Belchetz. 1994) . which are more likely to modify tamoxifen effects. Differences in hepatic synthesis include a higher oestradiol-oestrone ratio (Van Erpecum et al. 1991 : Walsh et al. 1994 ). a lack of induction of sex-hormone-binding globulin (Chetkowsky et al, 1986 , Van Erpecum et al. 1991 : Slowinska-Srzednicka et al. 1992 ) and a trend towards elevated insulin-like growth factor I concentrations (Weissberger et al. 1991 : Slowinska-Srzednicka et al. 1992 ) with the transdermal route of administration. As all these effects may exert a higher proliferative stimulation on the breast than oral HRT. the rationale for adding tamoxifen to transdermal HRT is further supported.
In conclusion, our results show no modification of the inhibitory effect of tarnoxifen on cardiovascular risk factors in women already on transdermal HRT. In contrast. a borderline adverse interaction on cholesterol measures was observed in those women who initiated HRT while already on tamoxifen intervention. The reduction of cholesterol by tamoxifen was greater with increasing age and higher baseline concentrations. Whereas our results provide the background for a trial of tamoxifen in women who already receive transdermal HRT. they suggest that HRT prescription during tamoxifen may attenuate its activity.
